Compare Quest Diagnostics Inc (DGX) vs Skyworks Solutions Inc (SWKS) Price & Performance

Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.

The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.

Skyworks Solutions (SWKS) trades at $80.75, down 3.21% today, with a bearish technical signal despite recent earnings beats. The company shows declining revenue and profit margins but maintains positive cash flow from operations. The pending Qorvo merger represents a significant strategic move, with regulatory clearances obtained and expected $500M in synergies. Valuation metrics include a P/E of 41.84 and P/S of 3.03, while analyst consensus leans bullish with 60% buy ratings.

The investment outlook balances merger synergies against fundamental deterioration. Near-term catalysts include the Qorvo deal closure and potential market share gains, but risks include integration challenges and ongoing margin pressure. The stock trades near analyst consensus targets, suggesting limited upside from current levels without operational improvements.